Results 351 to 360 of about 256,813 (405)

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue 5, Page 860-891, May 2025.
ABSTRACT Disease Overview Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the ...
Shai Shimony, Maximilian Stahl, Richard M. Stone   +2 more
wiley   +1 more source

Role of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. [PDF]

Clin Hematol Int
Mekni S, Ben Abdeljelil N, Ouerghi R, Kanoun RY, Frigui S, Belloumi D, Ben Yaiche I, Turki I, Chabaane A, Torjemane L, Ben Othman T.   +10 more
europepmc   +1 more source

Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report. [PDF]

Ann Hematol
Masuda Y, Sadato D, Toya T, Hirama C, Shimizu H, Najima Y, Harada H, Harada Y, Doki N.   +8 more
europepmc   +1 more source

Donor pretreatment with FLT-3 ligand augments anti-donor CTL, NK and LAK cell activities within liver allografts and alters the pattern of intragraft apoptotic activity [PDF]

, 1998
Chambers, FG, Fu, F, Fung, JJ, Li, W, Lu, L, Pan, F, Qian, S, Starzl, TE, Steptoe, RJ, Thomson, AW   +9 more
core  

Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria

American Journal of Hematology, Volume 100, Issue 5, Page 830-839, May 2025.
ABSTRACT Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high‐risk features on the clinical outcomes of adult patients meeting the updated TA‐TMA harmonizing criteria. Between 2005 and 2022,
Aldo A. Acosta‐Medina, Meera Sridharan, Ronald S. Go, Ann M. Moyer, Nelson Leung, Maria Alice V. Willrich, Robert Wolf, Rabee Kassis, Almothana Manasrah, Mira A. Kohorst, Urshila Durani, Aasiya Matin, Mehrdad Hefazi, Saad J. Kenderian, Abhishek A. Mangaonkar, Mithun V. Shah, Mark R. Litzow, William J. Hogan, David Dingli, Hassan B. Alkhateeb   +19 more
wiley   +1 more source

Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy. [PDF]

Ther Adv Hematol
Mandaci Şanli N, Ünal A.
europepmc   +1 more source

Substitution of Glutamic Acid at Position 71 of DRβ1*04:01 and Collagen‐Specific Tolerance Without Alloreactivity

Arthritis &Rheumatology, Volume 77, Issue 5, Page 526-535, May 2025.
Objective The DRB1 locus is strongly associated with both susceptibility and resistance to rheumatoid arthritis (RA). DRB1 alleles encoding the VKA or VRA epitope in positions 11, 71, and 74 confer the highest risk of developing RA, whereas the allele encoding VEA is protective.
Vibha Jha, Brian M. Freed, Elizabeth R. Sunderhaus, Jessica E. Lee, Edward B. Prage, Manjula Miglani, Edward F. Rosloniec, Jennifer L. Matsuda, Marilyne G. Coulombe, Amy S. McKee, Christina L. Roark   +10 more
wiley   +1 more source

Changes in Microbiome in Patients with Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation. [PDF]

Kidney360
Abramson MH, Sathick IJ, Knezevic A, Perales MA, Jaimes EA.   +4 more
europepmc   +1 more source

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Arthritis &Rheumatology, Volume 77, Issue 5, Page 571-581, May 2025.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges, Dinesh Khanna, Mark H. Wener, Matthew G. Mei, Maureen D. Mayes, Robert W. Simms, Vaishali Sanchorawala, Chitra Hosing, Suzanne Kafaja, Attaphol Pawarode, Leona A. Holmberg, Jason Kolfenbach, Daniel E. Furst, Keith M. Sullivan, Suiyuan Huang, Ted Gooley, Richard A. Nash   +16 more
wiley   +1 more source